NuCana Announces Grant of Composition-of-Matter Patent for NUC-7738 in Europe
NuCana announced the European Patent Office granted a composition-of-matter patent (EP 3683225) covering the chemical structure of NUC-7738, its lead anti-cancer agent. NUC-7738 is now protected by over 85 issued patents worldwide and is in the Phase 2 portion of the Phase 1/2 NuTide:701 study in combination with Keytruda for PD-1 inhibitor-resistant metastatic melanoma.
Key figures
- Drug Name
- NUC-7738
- Phase Of Trial
- Phase 2 (within Phase 1/2 NuTide:701)
- Cash runway
- into 2029
- Patent number eu
- EP 3683225
- Issued patents worldwide
- over 85
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.